Anacetrapib

Anacetrapib is a CETP inhibitor developed for the treatment of hypercholesterolemia and prevention of cardiovascular disease.

Overview

Chemical structure of Anacetrapib

Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor that was developed to treat hypercholesterolemia and prevent cardiovascular disease. It belongs to a class of drugs that work by inhibiting the CETP enzyme, which plays a role in the transfer of cholesterol esters and triglycerides between lipoproteins. By inhibiting CETP, anacetrapib increases high-density lipoprotein (HDL) cholesterol levels and decreases low-density lipoprotein (LDL) cholesterol levels.

Mechanism of Action

Anacetrapib functions by binding to the CETP enzyme, thereby inhibiting its activity. CETP is responsible for the exchange of cholesterol esters from HDL to other lipoproteins, such as LDL and very-low-density lipoprotein (VLDL). By inhibiting this process, anacetrapib leads to an increase in HDL cholesterol, which is often referred to as "good cholesterol," and a decrease in LDL cholesterol, known as "bad cholesterol."

Clinical Development

Anacetrapib was developed by Merck & Co. and underwent extensive clinical trials to evaluate its efficacy and safety. The drug showed promise in increasing HDL cholesterol levels and reducing LDL cholesterol levels in patients with hypercholesterolemia. However, despite its favorable effects on cholesterol levels, the clinical development of anacetrapib was eventually discontinued.

Potential Benefits

The primary benefit of anacetrapib was its ability to significantly increase HDL cholesterol levels while simultaneously reducing LDL cholesterol levels. This dual effect was considered advantageous for patients at risk of cardiovascular disease, as higher HDL levels are associated with a reduced risk of atherosclerosis and coronary artery disease.

Challenges and Discontinuation

Despite its potential benefits, the development of anacetrapib faced several challenges. Concerns about the long-term safety of CETP inhibitors, as well as mixed results from clinical trials of other drugs in the same class, contributed to the decision to halt its development. Additionally, the complexity of cardiovascular disease and the multifactorial nature of cholesterol metabolism posed challenges in demonstrating clear clinical benefits.

Related pages

• Cholesteryl ester transfer protein
• Hypercholesterolemia
• Cardiovascular disease
• High-density lipoprotein
• Low-density lipoprotein